Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Shuying Yang · UNIVERSITY OF PENNSYLVANIA · 2024 · $553,248 — Abstract. Rheumatoid arthritis (RA) is a debilitating chronic joint disease, causing functional disability, severe pain, joint deterioration, and substantial socioeconomic burdens. Presently, there is no cure for RA. While some patients manage RA with methotrexate and other disease-modifying anti-rh…
JENNIFER A DOUDNA · J. DAVID GLADSTONE INSTITUTES · 2024 · $236,250 — PROJECT SUMMARY/ABSTRACT The rapid development of genome editing tools has outpaced the ability to deliver these molecules specifically to diseased cells in human patients. A major bottleneck in expanding in vivo applications of genome editing is the lack of targeted, cell-specific delivery vehicles…
Bulent Ozpolat · METHODIST HOSPITAL RESEARCH INSTITUTE · 2024 · $351,075 — Project Summary Triple negative breast cancer (TNBC) has the worst prognosis and survival in all breast cancer subtypes with currently available standard therapies, representing an unmet therapeutic challenge. Significant heterogeneity (with six genetically defined subgroups) and a lack of FDA-appro…
Howard E Gendelman · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2024 · $690,750 — ABSTRACT Mononuclear phagocytes (MP; monocytes, macrophages, dendritic cells. and microglia) serve as human immunodeficiency virus type one (HIV-1) reservoirs, sites of viral persistence and latency, and inducers of end- organ disease. All are commonly linked to HIV-1 pathobiology. However, the key …
Zhaoyang Liu · UNIVERSITY OF SOUTHERN CALIFORNIA · 2024 · $236,917 — Project Summary Osteoarthritis (OA) is the most common form of degenerative joint disease affecting millions of people worldwide and lead to a tremendous financial burden. Currently there are no disease modifying therapies available for OA, due to limited understanding of the genetic factors and pat…
Kui Cui · BOSTON CHILDREN'S HOSPITAL · 2024 · $125,658 — Abstract The long-term goal of this proposal is developed to uncover the molecular mechanisms and identify critical regulators governing lymphatic vascular function in health and disease in hopes of offering potential new therapeutic targets to combat cardiovascular and metabolic disorders. At the t…
FENG C LIN · CLEVELAND CLINIC LERNER COM-CWRU · 2024 · $402,500 — Abstract Autoimmune uveitis, a common cause of blindness, has an unknown etiology and no known cure. We have been studying experimental autoimmune uveitis (EAU) induced in mice deficient in various complement components, inhibitors, or receptors following active immunization with a retinal antigen …
SATHY VENKAT BALU-IYER · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2024 · $465,506 — Project Summary: Autoimmune conditions, allergies and immunogenicity against therapeutic proteins are caused by unwanted immune responses against proteins. Our long-term goal is to rationally develop an immunotherapy platform using protein delivery strategies to treat these clinical conditions. We o…
Takahisa Kanekiyo · NORTH DAKOTA STATE UNIVERSITY · 2024 · $525,712 — SUMMARY/ABSTRACT: Alzheimer’s disease (AD) is a progressive neurodegenerative disease that has emerged as the most prevalent form of late-life dementia in humans. The accumulation, aggregation, and deposition of amyloid-β (Aβ) in the brain are central events in AD pathogenesis. Despite intense effor…
Hong Chen · BOSTON CHILDREN'S HOSPITAL · 2024 · $770,203 — PROJECT SUMMARY/ABSTRACT Atherosclerosis is the leading cause of life-threatening coronary heart disease, ischemic stroke, and peripheral arterial disease in the United States. Notably, dyslipidemia remains a major risk factor despite effective lipid- lowering therapies and prevention programs. This…
Hana Totary-Jain · UNIVERSITY OF SOUTH FLORIDA · 2024 · $476,323 — Atherosclerotic cardiovascular disease (CVD) represents a serious affliction affecting millions globally. Despite recent advances in pharmacological and percutaneous interventions, CVD remains the leading cause of death and disability in the world. One of the main therapeutic challenges facing ather…
ANUJ CHAUHAN · COLORADO SCHOOL OF MINES · 2024 · $242,946 — Meibomian gland dysfunction (MGD) is the leading cause of the dry eye disease which affects 6 to 7 million people in the United States. The Meibomian glands in MGD dry eye patients are unable to secrete oily lipids resulting in loss of the lipid layer on the surface of tears, leading to an increase …
William R. Freeman · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2024 · $413,374 — ABSTRACT Diabetic retinopathy is a leading cause of blindness in the industrialized world and has a global prevalence of an estimated 95 million people (1). Proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) originate from persistently elevated glucose levels leading to microv…
Ninh La-Beck · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · 2024 · $463,889 — ABSTRACT Drug delivery using liposomes increases tumor drug accumulation while sparing normal tissue. Several liposomal chemotherapies are approved to treat cancer. Unfortunately, lipid nanoparticles such as liposomes interact with the immune system and their impact on the tumor immunologic milieu i…
Jiandong Liu · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $662,922 — Cardiac fibroblasts (CFs) are the major cardiac cell type responsible for producing extracellular matrix (ECM) proteins, forming a structural scaffold crucial for supporting cardiac tissue during development and homeostasis. CFs are also known for their high plasticity, enabling them to swiftly resp…
Nehal N Mehta · MOBIUS SCIENTIFIC INC. · 2024 · $276,758 — Abstract The leading cause of blindness in people over 50 in industrialized nations including the United States is age-related macular degeneration (AMD). Early AMD is characterized by cholesterol accumulation under the neurosensory retina called sub-retinal drusenoid deposits or under the retinal …
Aria Pearlman Morales · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · 2024 · $53,974 — Project Summary and Abstract. The viability of a transplanted organ and the patient’s health are inherently limited by the burdens of immunosuppressive therapy, which must be used for the duration of the patient’s life. Systemic administration of these immunosuppressive agents increases the incidenc…
Jayoung Kim · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · 2024 · $222,000 — PROJECT SUMMARY / ABSTRACT The proposed project aims to deliver a research tool that supports accurate and resource- efficient biodistribution studies involving a library of gene-encapsulated nanoparticles. The state-of-the-art technology to perform in vivo high-throughput screening of non-viral gen…
Maksim Mezhericher · INAEDIS, INC · 2024 · $312,634 — Abstract INAEDIS proposes to develop a platform technology for rapid room temperature dehydration of vaccines and biopharmaceutical formulations using ultra-fine droplet aerosols, eliminating the need for logistically challenging cold chain infrastructure. Some 20% of pharmaceuticals ‒ around $35B i…
David Scott Johnson · GIGAMUNE, INC. · 2024 · $300,000 — PROJECT SUMMARY Project Title: In vivo Sickle Cell Disease Gene Therapy Using a Novel Virus Like Particle Organization: GigaMune, Inc. PI: David S. Johnson, Ph.D. β-hemoglobinopathies are the most common monogenic disorders worldwide. These autosomal recessive disorders affect the normal production …